[Doctor's Explanation] What Are Sex Chromosome Abnormalities Detected by NIPT? — Accuracy and How to Respond to a High-Risk Result —

Rewrite date: April 15, 2026

An expert explains in detail the sex chromosome abnormalities detectable by NIPT (Turner syndrome, Klinefelter syndrome, XYY syndrome, Triple X syndrome), including how they occur, detection accuracy and positive predictive value, how to respond to a high-risk result, and the importance of genetic counseling.

NIPT (Non-Invasive Prenatal Testing) was originally developed to detect autosomal abnormalities such as Down syndrome (trisomy 21) with high accuracy. By analyzing fetal-derived cell-free DNA (cfDNA) circulating in the mother's blood, this groundbreaking method allows fetal chromosomal abnormality risk to be assessed from a simple blood draw. Subsequent rapid advances in next-generation sequencing (NGS) technology have expanded the scope of analysis, and today "sex chromosome abnormalities" such as Turner syndrome and Klinefelter syndrome can also be screened for.

While the range of information available from the test has broadened, many people have questions and concerns such as "What exactly are sex chromosome abnormalities?", "What should I think if I get a high-risk result?", and "How does detection accuracy differ from autosomal abnormalities?" Because sex chromosome abnormalities are less widely recognized than conditions like Down syndrome, anxiety can sometimes outpace accurate information.

Recent international meta-analyses have reported that NIPT's screening performance for sex chromosome abnormalities tends to be inferior to that for autosomal trisomies, calling for a more cautious approach to interpreting results. The American College of Obstetricians and Gynecologists (ACOG) also clearly recommends that clinical decisions should never be based on NIPT results alone, and that a diagnosis should only be made after confirmatory testing.

This article systematically organizes the basic knowledge and mechanisms behind sex chromosome abnormalities detected by NIPT, what detection accuracy and positive predictive value (PPV) mean, and how to understand and approach a high-risk result — providing expert-level information to support calm, informed decision-making.(1)(2)(3)

What Are Sex Chromosome Abnormalities? Four Representative Conditions

Humans normally have 46 chromosomes (23 pairs): 22 pairs (44 chromosomes) are "autosomes," and the remaining pair (2 chromosomes) are the "sex chromosomes." Females typically have an XX combination and males an XY combination, but changes can occur in the number or structure of these sex chromosomes — collectively referred to as "sex chromosome abnormalities" (Sex Chromosome Aneuploidy: SCA).

Compared with autosomal abnormalities, sex chromosome abnormalities tend to have a relatively milder impact on life expectancy and daily functioning. However, the range of symptoms is extremely broad, and there is significant individual variation even within the same diagnosis, so accurate knowledge is essential. The four representative conditions targeted by NIPT are as follows.

Sex chromosome abnormalities are a type of "aneuploidy," meaning a deviation from the normal chromosome count of two (disomy). Whereas autosomal trisomies (three copies) often have a serious impact on life expectancy, sex chromosomes tend to result in a comparatively mild phenotype because a mechanism called "X-inactivation" suppresses expression of genes on the extra X chromosome. However, X-inactivation is not complete — some genes escape inactivation and continue to be expressed — and this is thought to be one cause of the various clinical symptoms associated with sex chromosome abnormalities.(2)(4)

Causes and Mechanisms Behind Sex Chromosome Abnormalities

Sex chromosome abnormalities primarily result from "nondisjunction" — a failure of chromosome pairs to separate correctly — during the "meiosis" process that forms eggs or sperm. Nondisjunction occurs when a pair of chromosomes that should separate fails to do so, resulting in a gamete with an extra chromosome or one that is missing a chromosome.

For example, if nondisjunction of the X chromosome occurs during egg formation, the result may be an egg containing XX or an egg containing no X at all. If the former is fertilized by a normal Y-bearing sperm, the result can be 47,XXY (Klinefelter syndrome); if the latter is fertilized by a normal X-bearing sperm, the result can be 45,X (Turner syndrome). Meanwhile, if nondisjunction of the Y chromosome occurs during sperm formation, 47,XYY (XYY syndrome) can result.

Importantly, these chromosomal abnormalities are in most cases random events, not inherited conditions. Neither parent is at fault, and it is best understood as a chromosomal change that can happen to anyone. While the incidence of some chromosomal abnormalities increases with advancing maternal age, some reports suggest that the association between maternal age and sex chromosome abnormalities is not as strong as it is for autosomal trisomies.

Nondisjunction can occur during either the first (MI) or second (MII) meiotic division, and it can also occur during early somatic cell division (mitosis) after fertilization. In the latter case, the result is called a "mosaic" form, in which cells with a normal chromosome makeup and cells with an abnormal chromosome makeup coexist in the body. In mosaic cases, clinical symptoms vary considerably depending on the proportion of abnormal cells, and symptoms are generally milder than in non-mosaic cases.(2)(4)

NIPT Detection Accuracy and Positive Predictive Value (PPV) for Sex Chromosome Abnormalities

NIPT analyzes fragments of fetal-derived cell-free DNA circulating in maternal blood using a next-generation sequencer. Many studies report detection accuracy for Down syndrome (trisomy 21) exceeding 99%, but it is important to know that detection accuracy for sex chromosome abnormalities is somewhat lower. This accuracy gap arises partly because changes in DNA quantity balance are harder to detect for sex chromosomes than for autosomes, and partly because the mother's own sex chromosome mosaicism can affect the result.

Specifically, the X chromosome carries far more genes than the Y chromosome (approximately 800–900 genes on the X chromosome versus only about 50–60 on the Y chromosome), making cfDNA signal interpretation more complex. Furthermore, if the mother has age-related mosaic loss of the X chromosome (mLOX) in her white blood cells, the ratio of sex chromosomes in maternal-derived DNA shifts, making it harder to accurately assess the fetus's sex chromosome status.(1)(2)

• The detection rate (sensitivity) for Turner syndrome is reported at 90.3%, with a specificity (the proportion of unaffected fetuses correctly identified as "unaffected") of 97.7%.(1)
• For sex chromosome trisomies (47,XXY, 47,XXX, and 47,XYY, including Klinefelter syndrome), the detection rate is 93.0%, with a specificity of 98.6%.(1)
• By comparison, Down syndrome (trisomy 21) has a reported detection rate of 99.7% and specificity of 99.96%, making the accuracy gap with sex chromosome abnormalities clear.(1)
• A large-scale meta-analysis published in 2019 also confirmed that NIPT's pooled sensitivity for sex chromosome abnormalities is statistically significantly lower than for autosomal trisomies.(2)

Watch Out for False Positives! Understanding "Positive Predictive Value"

A critically important concept here is "Positive Predictive Value (PPV)." PPV refers to "the proportion of people who test positive who actually have the condition," and it varies significantly not only with a test's sensitivity and specificity but also with the prevalence (pre-test probability) of the condition in question.

For example, studies estimating the PPV for Turner syndrome report a range of 14.5–32%. In other words, even when NIPT returns a high-risk result, more than half — and in some cases as much as about 85% — of the time there may actually be no abnormality. This surprisingly low PPV arises from several contributing factors, described below.

PPV is calculated using Bayes' theorem. If sensitivity is Sn, specificity is Sp, and prevalence is P, then PPV = (Sn × P) / (Sn × P + (1−Sp) × (1−P)). For conditions with low prevalence, like sex chromosome abnormalities (roughly 1/750–1/1,000), this formula shows that even a slight drop in specificity can dramatically reduce PPV. This is not unique to sex chromosome abnormalities — it is a statistical characteristic common to all screening tests.

• Confined Placental Mosaicism (CPM): Because most of the cfDNA analyzed by NIPT is derived from the placenta (chorion), a chromosomal abnormality present only in the placenta can be mistaken for a fetal abnormality. CPM occurs in about 1–2% of all pregnancies, and CPM involving sex chromosomes is reported to occur more frequently than CPM involving autosomes.
• Maternal sex chromosome mosaicism: If the mother herself has low-level sex chromosome mosaicism (such as age-related loss of the X chromosome), this can affect the test result. In women aged 40 and older, mosaic loss of the X chromosome in white blood cells has been reported to reach several percent.
• Vanishing twin: If one embryo of an initial twin pregnancy spontaneously disappears, its residual DNA can remain in the mother's blood and cause a false positive. cfDNA from a vanishing twin has been shown to be detectable well into later pregnancy.
• Maternal malignancy: In rare cases, cfDNA from an undiagnosed maternal malignancy (cancer) can affect NIPT results and cause a false positive.(3)

Accuracy Comparison with Autosomal Abnormalities and Key Points to Note

To understand NIPT's accuracy, it is very useful to compare detection accuracy for autosomal abnormalities (trisomy 21, trisomy 18, trisomy 13) with that for sex chromosome abnormalities. The table below summarizes the key indicators.(1)

As this table shows, the detection rate for sex chromosome abnormalities tends to be lower than for autosomal trisomies. Turner syndrome in particular has a detection rate of only 90.3%, meaning roughly 1 in 10 cases may go undetected (a false negative). Specificity is also somewhat lower, at 97.7% versus 99.96% for autosomal abnormalities, meaning a higher risk of false positives.

Another reason for this accuracy gap is the high prevalence of "mosaic forms" of Turner syndrome (45,X). In mosaic forms of 45,X (such as 45,X/46,XX), the chromosome makeup often differs between the placenta and the fetus, which affects NIPT's detection accuracy. Indeed, multiple studies have shown that mosaic Turner syndrome is harder for NIPT to detect than the non-mosaic form.

For this reason, when interpreting NIPT results it is essential to understand that testing for sex chromosome abnormalities is not as reliable as testing for autosomal abnormalities. It is recommended to think in advance, before undergoing testing, about how you would respond if a sex chromosome abnormality result comes back.(2)

Benefits and Limitations of Screening for Sex Chromosome Abnormalities with NIPT

Screening for sex chromosome abnormalities with NIPT offers several important benefits. First, obtaining information about the fetus's condition before birth allows medical and support systems to be prepared in advance after delivery. For example, early detection of Turner syndrome makes it possible to schedule detailed cardiovascular examinations from immediately after birth, providing an opportunity to detect and treat congenital heart conditions such as coarctation of the aorta at an early stage.

For Klinefelter syndrome or XYY syndrome, starting speech development and learning support early in childhood is said to contribute to improved long-term developmental outcomes. Obtaining information through prenatal diagnosis also offers the psychosocial benefit of giving parents time to prepare emotionally.

At the same time, the limitations of testing for sex chromosome abnormalities with NIPT must also be clearly understood.

• Not a definitive diagnosis: NIPT is a screening test, and a high-risk result only indicates an increased risk. Invasive testing is required for a definitive diagnosis.
• Relatively high false-positive rate: As noted above, the low PPV can lead to unnecessary anxiety and an increase in invasive testing.
• Difficulty detecting mosaic forms: Mosaic Turner syndrome in particular is difficult to detect, carrying a risk of false negatives as well.
• Psychological burden: Receiving unexpected information about a sex chromosome abnormality can cause significant psychological stress for expectant mothers and their partners. It has been pointed out that without adequate counseling support, this information can sometimes do more harm than good.(3)

Fully understanding these benefits and limitations before testing, and considering together with your partner whether you are prepared to receive this information, is the first step toward making effective use of NIPT.

What If a Sex Chromosome Abnormality Is Classified as "High Risk"?

It is entirely natural for expectant mothers and their partners to feel strong anxiety when NIPT returns a high-risk result for a sex chromosome abnormality. However, as noted above, given the PPV figures, it is important first to recognize that even with a high-risk result, it is more likely than not that the fetus has no abnormality. Here, we organize step by step how to think about and respond to a high-risk result.

Confirmatory Diagnosis Requires Invasive Testing

A "high-risk" result from NIPT is not a confirmed diagnosis. NIPT is strictly a screening test that assesses the level of risk. To reach a definitive diagnosis, invasive testing such as amniocentesis or chorionic villus sampling is required. These tests directly sample fetal cells for chromosome analysis and offer near-100% diagnostic accuracy, though they carry a small risk of miscarriage (about 0.1–0.3% for amniocentesis).

ACOG's 2020 practice report clearly recommends that, when NIPT returns a positive result for a sex chromosome abnormality, no irreversible decisions should be made based on that result before confirmatory testing. In confirmatory testing, combining conventional karyotype analysis using G-banding with fluorescence in situ hybridization (FISH) or chromosomal microarray analysis (CMA) can improve the detection accuracy of mosaic forms.(3)

The Concrete Steps Leading Up to Confirmatory Testing

Below is a general outline of the process from receiving a high-risk result to undergoing confirmatory testing.

1. Receive an explanation of the result from the NIPT testing facility or your attending physician
2. Schedule and attend genetic counseling to discuss the meaning of the result and your options for confirmatory testing with a specialist
   • Genetic counseling provides a comprehensive explanation of what the PPV figures mean, the clinical picture of each sex chromosome abnormality, and the risks and benefits of confirmatory testing
3. Consider undergoing confirmatory testing (amniocentesis or chorionic villus sampling), and decide together with your partner whether to proceed
4. Receive the confirmatory test results and discuss next steps with a genetic counselor or your physician
5. Coordinate with pediatric or specialist departments as needed to arrange post-birth support
   • For Turner syndrome, coordination with pediatric cardiology and pediatric endocrinology is especially important
   • For Klinefelter syndrome, coordination with endocrinology and urology is recommended

Appropriate Treatment and Support Can Improve Quality of Life

Even if a definitive diagnosis is made, the outlook for life after birth varies greatly depending on the specific condition and the individual. In many cases, appropriate medical intervention and support can substantially improve quality of life (QOL) for people with sex chromosome abnormalities.

In Klinefelter syndrome, testosterone replacement therapy from adolescence onward can be expected to help maintain bone density, improve muscle strength, and promote secondary sexual characteristics. In Turner syndrome, growth hormone therapy to improve height and estrogen replacement therapy to induce secondary sexual characteristics are established standard treatments. In recent years, advances in assisted reproductive technology have also expanded possibilities for pregnancy and childbirth that were previously considered difficult.

For growth hormone therapy in Turner syndrome, starting earlier is associated with a greater improvement in final adult height, and in some cases treatment starting at age 4–6 is recommended. Treatment can be expected to add an average of 5–8 cm in height and has also been shown to contribute to improved psychosocial self-esteem. Similarly, in men with Klinefelter syndrome, starting testosterone replacement therapy at an appropriate time has been reported to reduce the risk of metabolic syndrome and osteoporosis.(5)

Independent Social Life Is Possible in Most Cases

Regarding intellectual development, while mild learning challenges can occur in XYY syndrome and Triple X syndrome, in most cases affected individuals live within mainstream education and go on to work, marry, and raise children without difficulty. When detected early, interventions such as speech therapy and learning support can be started promptly, which means that obtaining information in advance through NIPT can itself be a meaningful benefit in many cases.

Some people may assume that "sex chromosome abnormality" equals "severe disability," but it is important, when facing a result, to recognize that in reality many affected individuals lead full, active social lives.

Large-scale follow-up studies have found that, compared with cases where a sex chromosome abnormality is discovered incidentally after birth, parents who are informed prenatally tend to be better psychologically prepared, which in turn tends to lead to more timely early support for the child. In other words, obtaining prenatal information through NIPT can lead not only to "anxiety from knowing" but also to "preparation and reassurance from knowing."(6)(7)

Using Genetic Counseling and Talking With Your Partner

To accurately understand this information and make decisions in line with your own values, making use of genetic counseling is strongly recommended. In genetic counseling, a certified genetic counselor or clinical genetics specialist can provide a comprehensive explanation of the medical significance of the test result, the risks and benefits of confirmatory testing, and the medical and social support available after a diagnosis.

In Japan, the certified genetic counselor system was established in 2005, and genetic counseling systems continue to be built out, primarily at university hospitals and perinatal centers nationwide. Genetic counseling is not a one-way provision of information but rather a process of "empathetic dialogue" that takes a non-directive stance in supporting the decision-making of the person being counseled. Ideally, it should be received both before testing (pre-test counseling) and after receiving results (post-test counseling).

It is also very important to share, from the moment results are received, the key points that should be discussed with your partner. Specifically, creating an environment in which both partners can discuss the following items based on the same information is essential to improving the quality of subsequent decision-making.

• Whether to undergo confirmatory testing (such as amniocentesis)
• How to think about continuing the pregnancy depending on the confirmatory test result
• What kind of support system will be needed for childcare after birth
• What medical institutions and support organizations are available
• How to share your feelings and concerns with each other
• At what stage to tell the child about the diagnosis in the future

Latest Research Trends on Sex Chromosome Abnormalities

NIPT technology continues to advance year by year, and research aimed at improving detection accuracy for sex chromosome abnormalities is being actively pursued internationally. Key research trends currently receiving attention include the following.

First is the development of technology to more precisely distinguish maternal-derived cfDNA from fetal-derived cfDNA. Approaches based on SNPs (single nucleotide polymorphisms) and analytical methods that exploit differences in methylation patterns are being explored to minimize the impact of maternal sex chromosome mosaicism on results.

Second is refinement of fetal fraction monitoring. NIPT's reliability depends heavily on the proportion of fetal-derived cfDNA in maternal blood (the fetal fraction), and when the fetal fraction is low (generally under 4%), the reliability of results drops significantly. The latest analysis platforms are increasingly incorporating systems that automatically flag results as "indeterminate" and recommend retesting when the fetal fraction is insufficient.

Third, the spread of whole-genome sequencing (WGS)-based NIPT is making it increasingly possible to detect chromosomal microdeletions and microduplications (copy number variants, or CNVs). In the future, it may become possible to assess structural sex chromosome abnormalities (such as partial deletions or translocations) using NIPT as well, although further evidence will be needed before this can be applied clinically.(2)

Summary: Understand the Result Correctly and Make a Decision You Can Accept

NIPT has made it possible to obtain advance information about sex chromosome abnormalities that were previously difficult to detect before birth. However, sex chromosome abnormalities encompass an extremely wide range of symptoms, and the impact on daily life can vary greatly between individuals even with the same diagnosis. Some conditions, such as Turner syndrome, tend to require relatively more medical follow-up, while many people with Triple X syndrome or XYY syndrome go through life undiagnosed, living entirely typical lives.

NIPT is, after all, only a "screening test" — a high-risk result is not a definitive diagnosis. Because the positive predictive value (PPV) for sex chromosome abnormalities in particular tends to be lower than for autosomal abnormalities, there is no need to feel immediately pessimistic upon receiving a high-risk result. What matters is understanding the true meaning of the result and making use of confirmatory testing and genetic counseling as needed.

Rather than being consumed by anxiety alone, it is important to organize accurate, evidence-based information, discuss it thoroughly with your partner and family, and work toward a decision that feels right for you. We hope you will keep in mind that NIPT is not a test that "provides an answer" but rather a test that "provides information," and that you will make calm use of the information it provides as material for your decision-making.

Many communities and support organizations exist both in Japan and abroad to support people with sex chromosome abnormalities and their families, and connecting with others who share similar experiences can provide both concrete information and emotional support. We hope that the information gained through NIPT can serve not as a source of anxiety but as a starting point for positive preparation.

\ Find out your risk of Down syndrome or a sex chromosome abnormality during pregnancy /

Frequently Asked Questions

Q1. What conditions can NIPT detect as sex chromosome abnormalities?

A. The four representative conditions are Turner syndrome (45,X), Klinefelter syndrome (47,XXY), XYY syndrome (47,XYY), and Triple X syndrome (47,XXX). All are caused by an abnormal number of sex chromosomes (aneuploidy), with a relatively high combined incidence of about 1 in 750 to 1 in 1,000 births, though the severity of symptoms varies greatly between individuals.(5)(6)(7)

Q2. How accurate is NIPT for detecting sex chromosome abnormalities?

A. The detection rate for Turner syndrome is reported at 90.3%, and for sex chromosome trisomies (47,XXY, 47,XXX, 47,XYY) at 93.0%. However, these figures are somewhat lower than the over-99% detection rate for autosomal abnormalities (such as trisomy 21), which is worth keeping in mind. In addition, the positive predictive value (PPV) varies depending on disease prevalence — for Turner syndrome it is estimated at around 14.5–32% — so it is important to understand that even a high-risk result carries a substantial chance of being a false positive.(1)(8)

Q3. What should I do if NIPT classifies a sex chromosome abnormality as "high risk"?

A. Because NIPT is a screening test, a definitive diagnosis requires invasive testing such as amniocentesis or chorionic villus sampling. It is recommended to first receive genetic counseling, where a specialist can explain the precise meaning of the result and the risks and benefits of confirmatory testing. From there, it is important to decide on next steps after thoroughly discussing them with your partner.(3)

Q4. If a sex chromosome abnormality is diagnosed, how will it affect my child's future?

A. Sex chromosome abnormalities generally have a milder impact on life expectancy than autosomal abnormalities, and in most cases affected individuals are able to lead typical social lives. Appropriate medical intervention — such as testosterone replacement therapy for Klinefelter syndrome, or growth hormone therapy and estrogen replacement therapy for Turner syndrome — can substantially improve quality of life. Where learning challenges arise, early support can lead to meaningful improvement.(5)

Q5. Why are false positives common for sex chromosome abnormalities on NIPT?

A. Common causes include confined placental mosaicism (CPM), maternal sex chromosome mosaicism (such as age-related loss of the X chromosome), and residual DNA from a vanishing twin. Because NIPT analyzes cfDNA derived mainly from the placenta rather than from fetal cells themselves, a false positive can occur when the chromosome makeup of the placenta differs from that of the fetus. For this reason, invasive testing is always required for a definitive diagnosis.(8)

Q6. Are sex chromosome abnormalities inherited? Is either parent at fault?

A. Most sex chromosome abnormalities arise from nondisjunction, a random event occurring during the formation of eggs or sperm. They are not an inherited type of condition, and neither parent is at fault. It is important to understand this as a chromosomal change that can happen to anyone.(4)

Q7. From how many weeks can NIPT test for sex chromosome abnormalities?

A. NIPT is generally available from week 10 of pregnancy onward, by which point the amount of fetal-derived cfDNA (fetal fraction) in maternal blood is sufficient for analysis. However, because fetal fraction varies with maternal body size (a higher BMI tends to lower fetal fraction) and gestational age, it is recommended to consult with your physician about the appropriate timing for the blood draw.(2)

[References]

(1) Nature, July 2009
(2) seeDNA Genetic Testing & DNA Paternity Testing, April 2026
(3) Appl Biochem Biotechnol, August 2017
(4) J Colloid Interface Sci, February 2019
(5) PMC, November 2022
(6) Homeopathy, August 2016
(7) Center for Chronic Pediatric Diseases of Specified Categories, October 2014
(8) SpringerLink, January 2023